W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
William W. Busse,Geoffrey L. Chupp,Hiroyuki Nagase,Frank C. Albers,S Doyle,Qin Shen,Daniel J. Bratton,Necdet B Gunsoy +7 more
TL;DR: This indirect treatment comparison (ITC) of the licensed doses suggests that mepolizumab was associated with significantly greater improvements in clinically significant exacerbations and asthma control compared with resl Lizumab or benralIZumab in patients with similar blood eosinophil counts.
Journal ArticleDOI
Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.
TL;DR: Single oral doses of montelukast 100 mg and 250 mg produced significant increases in FEV1 irrespective of the concurrent use of inhaled corticosteroids in asthmatic subjects with airflow limitation.
Journal ArticleDOI
Allergy and asthma
TL;DR: In this review key findings published in 2004 issues of the Journal of Allergy and Clinical Immunology are highlighted to demonstrate recent advances in these areas.
Journal ArticleDOI
Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
Stephen T. Holgate,Michael Noonan,P. Chanez,William W. Busse,Lieven Dupont,Ian D. Pavord,Arja L. Hakulinen,L. Paolozzi,Joseph Wajdula,C. Zang,H. Nelson,D. Raible +11 more
TL;DR: Clinical efficacy of ETN was not shown in subjects with moderate-to-severe persistent asthma over 12 weeks, however, ETN treatment was a well-tolerated therapy and studies in specific subsets of patients with asthma with longer-term follow-up may be needed to fully evaluate the clinical efficacy.
Journal ArticleDOI
Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways.
Brian D. Modena,John Tedrow,Jadranka Milosevic,Eugene R. Bleecker,Deborah A. Meyers,Wei Wu,Ziv Bar-Joseph,Serpil C. Erzurum,Benjamin Gaston,William W. Busse,Nizar N. Jarjour,Naftali Kaminski,Sally E. Wenzel +12 more
TL;DR: These findings show that bronchial epithelial cell gene expression, as related to the asthma biomarker FeNO, can identify distinct asthma phenotypes, while also suggesting the presence of underlying novel gene pathways relevant to these phenotypes.